Celyad Oncology SA (CYAD.BR)
Company Info
Highlights
€17.01M
-€1.36
€14.00K
€5.00K
-€2.79M
€0.21 - €1.22
€0.50
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of €10,000 in Celyad Oncology SA, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Celyad Oncology SA had a return of -42.35% year-to-date (YTD) and 10.05% in the last 12 months. Over the past 10 years, Celyad Oncology SA had an annualized return of -36.89%, while the S&P 500 had an annualized return of 11.33%, indicating that Celyad Oncology SA did not perform as well as the benchmark.
CYAD.BR
-42.35%
-21.06%
63.55%
10.05%
-46.35%
-36.89%
^GSPC (Benchmark)
3.96%
1.97%
10.09%
22.16%
12.70%
11.33%
Monthly Returns
The table below presents the monthly returns of CYAD.BR, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -39.61% | -42.35% | |||||||||||
| 2024 | 3.33% | -5.46% | -7.87% | -7.41% | -6.46% | -7.89% | -9.46% | 2.37% | 3.47% | 3.91% | 162.01% | -2.60% | 82.56% |
| 2023 | 170.75% | -18.25% | -24.02% | -22.44% | -20.30% | -0.76% | -2.30% | 47.45% | -15.69% | -10.41% | -29.58% | -2.50% | -22.92% |
| 2022 | -8.82% | -22.00% | -14.40% | -9.07% | 0.21% | -10.87% | -0.12% | 15.09% | -25.43% | -27.92% | -6.89% | -49.40% | -85.60% |
| 2021 | 0.15% | -3.32% | -5.62% | -11.07% | -12.36% | -6.26% | -18.55% | 3.61% | -2.95% | 4.97% | -13.16% | 6.52% | -46.90% |
| 2020 | 2.37% | -19.84% | -14.57% | 25.15% | 18.68% | -3.56% | -13.55% | 1.54% | -2.11% | -24.49% | 29.75% | -19.27% | -31.75% |
| 2019 | 16.52% | -6.36% | 3.70% | -1.23% | -5.61% | -41.71% | 8.63% | 0.54% | -20.02% | -9.99% | 39.65% | -13.39% | -41.53% |
| 2018 | 9.97% | -14.61% | -13.05% | 0.92% | -8.35% | -2.68% | 2.75% | -0.92% | -12.05% | -3.34% | 10.35% | -31.73% | -52.07% |
| 2017 | 13.14% | 2.78% | 17.33% | 20.78% | 35.35% | -6.81% | -23.93% | 34.34% | 26.57% | 4.49% | -30.21% | -0.87% | 94.33% |
| 2016 | -33.26% | 16.07% | 3.01% | 5.00% | 20.10% | -54.83% | -0.05% | -10.41% | -4.57% | -17.10% | 10.56% | 3.37% | -63.20% |
| 2015 | 27.70% | 6.49% | -4.66% | 17.11% | 30.93% | -30.03% | 7.08% | -14.42% | -17.03% | -0.24% | 25.77% | 7.60% | 42.77% |
| 2014 | 76.13% | -9.31% | -4.53% | -7.44% | 9.54% | 7.82% | -7.84% | -0.66% | -0.35% | -9.97% | 2.06% | -5.04% | 32.68% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of CYAD.BR is 56, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Celyad Oncology SA (CYAD.BR) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Celyad Oncology SA. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Celyad Oncology SA was 99.67%, occurring on Sep 10, 2024. The portfolio has not yet recovered.
The current Celyad Oncology SA drawdown is 99.41%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.67% | May 25, 2015 | 2383 | Sep 10, 2024 | — | — | — |
| -42.35% | Jan 22, 2014 | 233 | Dec 17, 2014 | 77 | Apr 10, 2015 | 310 |
| -38% | Jul 9, 2013 | 69 | Oct 11, 2013 | 16 | Nov 4, 2013 | 85 |
| -18.49% | Nov 13, 2013 | 7 | Nov 21, 2013 | 25 | Dec 30, 2013 | 32 |
| -14.22% | Jan 13, 2014 | 2 | Jan 14, 2014 | 3 | Jan 17, 2014 | 5 |
Volatility
Volatility Chart
The current Celyad Oncology SA volatility is 12.97%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Celyad Oncology SA.
Loading data...
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |